Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fracturesMatthew Austin, Michael A. Bolognese, Claus Christiansen et al.|Journal of Bone and Mineral Research|2011Cited by 181
Differing effects of denosumab and alendronate on cortical and trabecular boneRoger Zebaze, Ego Seeman, Cesar Libanati et al.|Bone|2013Cited by 155
Changes in lumbar spine QCT, DXA and TBS with denosumab, alendronate or placebo in postmenopausal women with low bone massThierry Thomas, Cesar Libanati, Angela M. Cheung et al.|Bone Abstracts|2014Cited by 2
THE TRANSITORY PTH INCREASE FOLLOWING DENOSUMAB ADMINISTRATION IS ASSOCIATED WITH REDUCED INTRACORTICAL POROSITY: A DISTINCTIVE CHARACTERISTIC OF DENOSUMAB THERAPYEgo Seeman, John P. Bilezikian, Cesar Libanati et al.|Osteoporosis International|2012Cited by 1